Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Olaplex Reports 9.8% Decrease in Fourth Quarter Net Sales

Olaplex Holdings, Inc. (NASDAQ: OLXP) has released its financial results for the fourth quarter and fiscal year ending December 31, 2024. The company reported a decrease in net sales of 9.8% for the fourth quarter, amounting to $100.7 million. The breakdown by channel shows that specialty retail increased by 5.7% to $28.8 million, while professional decreased by 27.1% to $31.0 million and direct-to-consumer decreased by 2.5% to $40.9 million.

Looking at the fiscal year 2024 compared to 2023, Olaplex reported a 7.8% decrease in net sales, amounting to $422.7 million. The breakdown by channel reveals that specialty retail increased by 5.4% to $142.3 million, while professional decreased by 19.3% to $145.3 million and direct-to-consumer decreased by 5.7% to $135.0 million.

The company's net income for the fourth quarter decreased by 162.4%, and adjusted net income decreased by 65.8%. The diluted earnings per share (EPS) stood at $(0.01) compared to $0.02 for the fourth quarter of 2023, while the adjusted diluted EPS was $0.01 compared to $0.03 for the same period last year.

For the fiscal year 2024, net income decreased by 68.3%, and adjusted net income decreased by 30.1%. The diluted EPS amounted to $0.03 compared to $0.09 for 2023, and the adjusted diluted EPS was $0.11 compared to $0.16 for 2023.

The adjusted gross profit margin for the fourth quarter decreased to 68.6% from 70.6% in the same period of 2023, while the adjusted SG&A increased by 13.0%. In the fiscal year 2024, the adjusted gross profit margin remained at 71.4%, whereas the adjusted SG&A increased by 11.2%.

These figures provide insight into Olaplex's performance and indicate notable changes in key financial metrics compared to the previous periods. Today the company's shares have moved 23.9% to a price of $1.71. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS